Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Alessandro Sciarra
 -- 1774 2023-09-12 08:00:16 |
2 layout & references
Sirius Huang
 Meta information modification 1774 2023-09-13 03:00:11 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Sciarra, A.; Santarelli, V.; Santodirocco, L.; Frisenda, M.; Salciccia, S.; Casale, P.; Forte, F.; Mariotti, G.; Moriconi, M.; Cattarino, S.; et al. PARP Inhibition in Prostate Cancer Patients. Encyclopedia. Available online: https://encyclopedia.pub/entry/49051 (accessed on 05 August 2024).
Sciarra A, Santarelli V, Santodirocco L, Frisenda M, Salciccia S, Casale P, et al. PARP Inhibition in Prostate Cancer Patients. Encyclopedia. Available at: https://encyclopedia.pub/entry/49051. Accessed August 05, 2024.
Sciarra, Alessandro, Valerio Santarelli, Lorenzo Santodirocco, Marco Frisenda, Stefano Salciccia, Paolo Casale, Flavio Forte, Gianna Mariotti, Martina Moriconi, Susanna Cattarino, et al. "PARP Inhibition in Prostate Cancer Patients" Encyclopedia, https://encyclopedia.pub/entry/49051 (accessed August 05, 2024).
Sciarra, A., Santarelli, V., Santodirocco, L., Frisenda, M., Salciccia, S., Casale, P., Forte, F., Mariotti, G., Moriconi, M., Cattarino, S., Sciarra, B., Bevilacqua, G., & Gentilucci, A. (2023, September 12). PARP Inhibition in Prostate Cancer Patients. In Encyclopedia. https://encyclopedia.pub/entry/49051
Sciarra, Alessandro, et al. "PARP Inhibition in Prostate Cancer Patients." Encyclopedia. Web. 12 September, 2023.
PARP Inhibition in Prostate Cancer Patients
Edit
This entry is adapted from the peer-reviewed paper 10.3390/curroncol30090584

The increasing diffusion of genetic analysis regarding the pathogenetic variants (PVs) of genes involved in DNA Damage Repair (DDR) mechanisms and the development of Poly ADP ribose polymerase (PARP) inhibitors (PARPis) led to the first valid precision medicine option tailored toward metastatic prostate cancer (mPC). The concept of anticipation in the systemic treatment of mPC was initially adopted for androgen receptor signaling inhibitors (ARSIs) to describe the expansion of their indications, from the setting of the late-stage second-line treatment of metastatic castration-resistant prostate cancer (mCRPC) to first-line therapy in selected cases. There is already mounting evidence in favor of the anticipation of PARPis in the first line of mCRPC therapy, and further evidence in favor of mHSPC is emerging. 

prostate cancer PARP inhibitors DDR gene CRPC

1. Introduction: The Concept of Anticipation in the Systemic Therapy of Prostate Cancer

For a long time, the natural history of metastatic prostate cancer (mPC) has been simply divided into two separate phases: 1. hormone-sensitive (HSPC) and 2. hormone-refractory (HRPC), subsequently better defined as castration-resistant (CRPC). These two phases were considered two distinct diseases with different therapeutic approaches, with the first subjected to different lines of manipulation of the classic androgen deprivation therapy (ADT), and the second to chemotherapy (CHT) with taxanes. The systemic treatment of mPC has undergone an epochal positive evolution in recent years, in particular with the development of new-generation hormone manipulations and androgen receptor signaling inhibitors (ARSIs). Most of these new therapies were initially indicated in the late stages of the disease (post CHT-mCRPC) [1][2] where options and patient survival were limited. However, several clinical trials have shown that ARSIs and CHT are equally effective in earlier stages, such as first-line mHSPC [3][4][5][6]. The intention of treating more patients for a longer time has led to the concept of anticipation in the systemic treatment of mPC, which brought several changes to therapeutic strategies, including the following: 1. the use of both docetaxel and ARSIs in mHSPC; 2. the stratification of mPC in classes such as high- and low-volume, high- and low-risk or de novo and progressive tumors; 3. competition in the use of these drugs between the mHSPC and mCRPC phases; and 4. the shift from a clear distinction between the HSPC and CRPC phases and their management to a merger of the two. At present, the management of mCRPC represents a second line of therapy, sharing several of the recommended drugs with mHSPC. The concept of the anticipation of therapy has merged with that of the intensification of care, leading to first-line therapeutic schemes with doublets or triplets of drugs in mHSPC. As a matter of fact, ADT alone no longer represents a therapeutic option in mHSPC, and the current recommendation is for an association with ARSIs, docetaxel or both [3][4][5][6]. In patients with high-volume/high-risk de novo mHSPC, the recent trials PEACE1 [7] and ARASENS [8] introduced the concept of triplets, with abiraterone or daralutamide in combination with docetaxel and ADT.
The main criticalities associated with the concepts of anticipation and intensification of care are the development of early drug resistance and the limited choice of treatment for late mCRPC, with the need to repeat the same combination of drugs used as in first-line therapies for HSPC. The key turning point in this scenario, emphasized by the numerous therapeutic options available, is the identification of valid prognostic indicators of treatment response and the development of personalized therapies for each patient. The stratification of mPC on the basis of the volume, risk and development of the disease is not sufficient for precision medicine. The genetic analysis of the pathogenetic variants (PVs) of genes involved in DNA Damage Repair (DDR) mechanisms and the development of Poly ADP ribose polymerase (PARP) inhibitors (PARPis) led to the first valid precision medicine options tailored toward mPC. PARPis are following the same evolutionary path as that traced by ARSIs, expanding their indications starting from the late stage of second-line mCRPC treatment in a limited population and time frame. Inevitably, PARPis will also be absorbed by the concepts of the anticipation and intensification of care. There is already mounting evidence in favor of the anticipation of PARPis in the first line of mCRPC therapy, and further evidence in favor of mHSPC is emerging (Figure 1).
Figure 1. The concepts of the anticipation and intensification of care in the systemic therapy of metastatic PC and the ways in which PARP inhibitors and HRR genetic analysis are involved (mCRPC = metastatic castration-resistant prostate cancer; mHSPC = metastatic hormone-sensitive prostate cancer; nmCRPC = non-metastatic castration-resistant prostate cancer; PFS = progression-free survival; HR = hazard ratio; HRR = homologous recombinant repair; ABI = abiraterone; ENZA = enzalutamide; PARPi = Poly ADP ribose polymerase inhibitor).

2. The Rationale and the Genetic Profiles That Sustain PARP Inhibitors in PC

To address the underlying issue of genomic erosion, a complex network of DDR mechanisms has evolved [9][10]. Genetic abnormalities in DDR response systems are associated with life-threatening diseases such as immune deficiency, premature aging and cancer susceptibility. The following are the principal DNA repair pathways: single-strand break repair (SSR), mismatch repair (MMR), base excision repair (BER), homologous recombination repair (HRR), non-homologous end joining (NHEJ) and nucleotide excision repair (NER). With a single-strand break in DNA, the second intact strand represents a template for BER and NER repair. A double-strand break (DSB) activates the HRR, MMR and NHEJ mechanisms [11][12]
PARP is a multifunctional protein that plays a critical role in SSR and BER mechanisms, primarily by recruiting DNA repair proteins to the sites of damage. So far, eighteen members of the PARP family have been found, among which PARP-1 is the most important [13]. PARP’s main enzymatic function is to add ADP-ribose to substrate proteins by cleaving NAD+ and releasing nicotinamide, thus activating a complex cascade, which ends in the recruitment of different proteins, such as DNA polymerase theta (POLQ), DNA ligase I and XRCC1, to the site of damage. Despite being well-known for its role in SSR and BER, recent evidence suggests that PARP can also affect DSB repair, mainly by controlling the expression of the key HR genes BRCA1 and RAD51 [14][15][16].
Defects in the DDR pathways can result in genomic instability and gene mutations, and, eventually, lead to the development of cancer. On the other hand, germline or acquired mutations in DDR also provide cancer-specific vulnerabilities that can be targeted by synthetic lethality-based therapies [17]. PARPis are the first successful example of a targeted therapy that uses synthetic lethality to kill cancerous cells with DNA-repairing deficiencies (e.g., BRCA1/2 mutation). These drugs act by competing with NAD+ for the catalytically active sites of PARP molecules, interfering with SSB repair by BER. The unrepaired SSB can be converted to DSB, and the primary mechanism in the repair of such lesions during the cell cycle is HRR. While HRR-proficient cells can repair the DSB originating from the SSB, thus ensuring genetic stability and cell survival, HRR-deficient cells are unable to do so, resulting in apoptosis and, ultimately, cell death [16][17][18]. Olaparib was the first drug to be developed in this group, initially approved in 2014 for patients with ovarian cancer with germline BRCA PVs and subsequently for those with breast, pancreatic and prostate cancer [19].
Germline HRR PVs increase the risk of developing PC by eight times at the age of 65 years and are linked to more aggressive PC, a higher risk of lymph-node invasion and distant metastasis at the time of diagnosis [20]. Moreover, germline BRCA 1/2 PVs are associated with a higher probability of failure in patients with localized disease undergoing active surveillance and a higher risk of recurrence in patients who have undergone curative treatment [21][22]. Several studies have analyzed the prevalence of germline and somatic mutations in HRR genes, both in metastatic and localized PC. A 2019 systematic review by Lang et al. [23] found a median prevalence of germline HRR PVs, and specifically of BRCA2 PVs, in patients with familiar PC rates of 29.3% (range, 7.3–91.67%) and 3.7% (range, 1.3–7.9%), respectively. In the same study, for unselected patients, the frequencies of somatic and germline mutations were, respectively, 3.9% and 1.5% for ATM, 1.1% and 0.6% for BRCA1, 4.9% and 1.1% for BRCA2, 1.3% and 0.5% for PALB2 and 1.5% and 0.5% for RAD51C. The overall prevalence of somatic DDR gene PVs ranged between 4.9 and 22%, while the rate of germline DDR PVs was 17.2–19%.
Regarding metastatic PC, the incidence of germline PVs in HRR genes was found to be between 11% and 33% in a pan-cancer analysis of whole genomes [23]. Similarly, 8% of germline and 23% of somatic HRR PVs were found in 150 metastatic PCs by the International Stand Up to Cancer/Prostate Cancer Foundation team (SU2C-PCF) [24]. In this cohort, BRCA2 was the most prevalent mutation (13%) followed by ATM (7.3%), MSH2 (2%) and BRCA1. More specifically, in mCRPC, the incidence of somatic HRR PVs was 24% (BRCA 13%, ATM 7.3%, MSH2 2%, BRCA1 0.3%) in a study by Eeles et al. [25] and 28% in the Profound study, which analyzed the results of 2792 biopsies of mCRPC patients.
Considering localized PC, the rates of PVs in HRR seem to be lower than those seen in mPC. Despite this, a 2019 study by Kim et al. [26] found an overall incidence of HRR pathway alteration in localized PC of 29.9%, higher than that suggested by a previous study by Marshall et al. [27] (11% in Gleason Grade Group 5 and 15.8% in cT3 patients).
The Profound study represents the biggest resource of tissue samples, with a total of 4858 centrally tested [28]. Next-Generation Sequencing (NGS) was performed mainly on primary tumor samples (83%). It is relevant to underline that of these primary samples, 96% were archival and 4% newly obtained. Samples from metastases were obtained in 17% of cases, and again, most were archival (60% archival and 33% newly obtained). This sample was found to be suitable for testing at similar percentages between the newly obtained and archival samples (63.9% vs. 56.9%) and between the metastatic and primary samples (63.9% vs. 56.2%). On the contrary, the NGS results significantly declined with increasing sample age.
The somatic analysis of HRR mutations in PC should be used instead of germline analysis, when possible. A biopsy of metastatic lesions is the ideal method to identify the molecular changes that occur during disease progression. Despite this, biopsies of metastatic sites are challenging and not always feasible, and results from a single site may underestimate tumor heterogeneity. In the future, the analysis of free circulating DNA (cDNA) might overcome the issues associated with tissue biopsy, such as invasiveness, the need for anesthesia and pain. The first study to analyze cDNA in this field was the GHALAND study [29], where an analysis of treatment efficacy was performed on the basis of the amount of circulating tumor cells present from the eighth week of treatment. The BRCA cohort obtained better results when compared to the non-BRCA cohort, with a 24% CTC (circulating tumor cell) response. However, incongruences with the different commercial tests currently available for the analysis of cDNA are as high as 40%, with the risk of patients receiving inadequate or no treatment.

References

  1. Poon, D.M.; Chan, K.; Lee, S.H.; Chan, T.W.; Sze, H.; Lee, E.K.; Lam, D.; Chan, M.F. Abirateroneacetate in metastatic castration-resistant prostate cancer-the unanticipated real-world clinical experience. BMC Urol. 2016, 16, 12–18.
  2. Beer, T.M.; Armstrong, A.J.; Rathkopf, D.; Loriot, Y.; Sternberg, C.N.; Higano, C.S.; Iversen, P.; Evans, C.P.; Kim, C.-S.; Kimura, G.; et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur. Urol. 2017, 71, 151–154.
  3. Armstrong, A.J.; Szmulewitz, R.Z.; Petrylak, D.P.; Holzbeierlein, J.; Villers, A.; Azad, A.; Alcaraz, A.; Alekseev, B.; Iguchi, T.; Shore, N.D.; et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy with Enzalutamide or Placebo in Men with Metastatic Hormone-Sensitive ProstateCancer. J. Clin. Oncol. 2019, 37, 2974–2986.
  4. Chi, K.N.; Chowdhury, S.; Bjartell, A.; Chung, B.H.; Gomes, A.J.P.d.S.; Given, R.; Juárez, A.; Merseburger, A.S.; Özgüroğlu, M.; Uemura, H.; et al. Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J. Clin. Oncol. 2021, 39, 2294–2303.
  5. Fizazi, K.; Tran, N.; Fein, L.; Matsubara, N.; Rodriguez-Antolin, A.; Alekseev, B.Y.; Özgüroğlu, M.; Ye, D.; Feyerabend, S.; Protheroe, A.; et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019, 20, 686–700.
  6. Kyriakopoulos, C.E.; Chen, Y.-H.; Carducci, M.A.; Liu, G.; Jarrard, D.F.; Hahn, N.M.; Shevrin, D.H.; Dreicer, R.; Hussain, M.; Eisenberger, M.; et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J. Clin. Oncol. 2018, 36, 1080–1087.
  7. Fizazi, K.; Foulon, S.; Carles, J.; Roubaud, G.; McDermott, R.; Fléchon, A.; Tombal, B.; Supiot, S.; Berthold, D.; Ronchin, P.; et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022, 399, 1695–1707.
  8. Smith, M.R.; Hussain, M.; Saad, F.; Fizazi, K.; Sternberg, C.N.; Crawford, E.D.; Kopyltsov, E.; Park, C.H.; Alekseev, B.; Montesa-Pino, Á.; et al. Darolutamide andSurvival in Metastatic, Hormone-Sensitive Prostate Cancer. N. Engl. J. Med. 2022, 386, 1132–1142.
  9. Sciarra, A.; Frisenda, M.; Bevilacqua, G.; Gentilucci, A.; Cattarino, S.; Mariotti, G.; Del Giudice, F.; Di Pierro, G.B.; Viscuso, P.; Casale, P.; et al. How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients. Int. J. Mol. Sci. 2022, 24, 674.
  10. Sciarra, A.; Fiori, C.; Del Giudice, F.; DIPierro, G.; Bevilacqua, G.; Gentilucci, A.; Cattarino, S.; Mariotti, G.; Salciccia, S. DDR genes analysis and PARP-inhibitors therapy as tailored management in metastatic prostate cancer: Achieved answers, open questions and future perspectives. Minerva Urol. Nephrol. 2022, 74, 649–652.
  11. Giglia-Mari, G.; Zotter, A.; Vermeulen, W. DNA damage response. Cold Spring Harb. Perspect. Biol. 2011, 3, a000745.
  12. Caldecott, K.W. Mammalian single-strand break repair: Mechanisms and links with chromatin. DNA Repair 2007, 6, 443–453.
  13. Rouleau, M.; Patel, A.; Hendzel, M.J.; Kaufmann, S.H.; Poirier, G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010, 10, 293–301.
  14. Liu, C.; Vyas, A.; Kassab, M.A.; Singh, A.K.; Yu, X. The role of poly ADP-ribosylation in the first wave of DNA damage response. Nucleic Acids Res. 2017, 45, 8129–8141.
  15. Ceccaldi, R.; Liu, J.C.; Amunugama, R.; Hajdu, I.; Primack, B.; Petalcorin, M.I.R.; O’connor, K.W.; Konstantinopoulos, P.A.; Elledge, S.J.; Boulton, S.J.; et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature 2015, 518, 258–262.
  16. Hegan, D.C.; Lu, Y.; Stachelek, G.C.; Crosby, M.E.; Bindra, R.S.; Glazer, P.M. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc. Natl. Acad. Sci. USA 2010, 107, 2201–2206.
  17. Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.J.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434, 917–921.
  18. Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434, 913–917.
  19. Domchek, S.M.; Aghajanian, C.; Shapira-Frommer, R. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol. Oncol. 2016, 140, 199–203.
  20. Castro, E.; Goh, C.; Olmos, D. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J. Clin. Oncol. 2013, 31, 1748–1757.
  21. Carter, H.B.; Helfand, B.; Mamawala, M. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Eur. Urol. 2019, 75, 743–749.
  22. Castro, E.; Goh, C.; Leongamornlert, D.; Saunders, E.; Tymrakiewicz, M.; Dadaev, T.; Govindasami, K.; Guy, M.; Ellis, S.; Frost, D.; et al. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. Eur. Urol. 2015, 68, 186–193.
  23. Lang, S.H.; Swift, S.L.; White, H.; Misso, K.; Kleijnen, J.; Quek, R.G. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int. J. Oncol. 2019, 55, 597–616.
  24. ICGC/TCGA. Pan-Cancer Analysis of Whole Genomes Consortium. Pan-Cancer Anal. Whole Genomes Nat. 2020, 578, 82–93.
  25. Eeles, R.; Goh, C.; Castro, E.; Bancroft, E.; Guy, M.; Al Olama, A.A.; Easton, D.; Kote-Jarai, Z. The genetic epidemiology of prostate cancer and its clinical implications. Nat. Rev. Urol. 2014, 11, 18–31.
  26. Kim, I.E., Jr.; Kim, S.; Srivastava, A. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urol. 2019, 19, 33.
  27. Marshall, C.H.; Fu, W.; Wang, H.; Baras, A.S.; Lotan, T.L.; Antonarakis, E.S. Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: Association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis. 2019, 22, 59–65.
  28. Hussain, M.; Corcoran, C.; Sibilla, C.; Fizazi, K.; Saad, F.; Shore, N.; Sandhu, S.; Mateo, J.; Olmos, D.; Mehra, N.; et al. Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). Clin. Cancer Res. 2022, 28, 1518–1530.
  29. Smith, M.R.; Scher, H.I.; Sandhu, S.; Efstathiou, E.; Lara, P.N., Jr.; Yu, E.Y.; George, D.J.; Chi, K.N.; Saad, F.; Ståhl, O. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): A multicentre, open-label, phase 2 trial. Lancet Oncol. 2022, 23, 362–373.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Alessandro Sciarra
,
Valerio Santarelli
,
Lorenzo Santodirocco
,
Marco Frisenda
,
Stefano Salciccia
,
Paolo Casale
,
Flavio Forte
,
Gianna Mariotti
,
Martina Moriconi
,
Susanna Cattarino
,
Beatrice Sciarra
,
Giulio Bevilacqua
,
Alessandro Gentilucci
View Times: 205
Revisions: 2 times (View History)
Update Date: 13 Sep 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback